Use the Back button in your browser to see the other results of your search or to select another record.
Device-guided breathing as treatment for hypertension in type 2 diabetes mellitus: a randomized, double-blind, sham-controlled trial |
Landman GWD, Drion I, van Hateren KJJ, van Dijk PR, Logtenberg SJJ, Lambert J, Groenier KH, Bilo HJG, Kleefstra N |
JAMA Internal Medicine 2013 Jul 22;173(14):1346-1350 |
clinical trial |
9/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: Yes; Blind subjects: Yes; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: Yes; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed* |
IMPORTANCE: Biofeedback with device-guided lowering of breathing frequency could be an alternate nonpharmacologic treatment option for hypertension. Evidence from trials with high methodologic quality is lacking. OBJECTIVE: To evaluate the effects of device-guided lowering of breathing frequency on blood pressure in patients with type 2 diabetes mellitus and hypertension. DESIGN: Single-center, double-blind, sham-controlled trial. SETTING: A large nonacademic teaching hospital in the Netherlands. PARTICIPANTS: Patients with type 2 diabetes mellitus and hypertension. INTERVENTION: Fifteen-minute sessions with either the device that guides breathing through musical tones to a lower breathing frequency (aiming at < 10 breaths/min) or a sham device (music without aiming at lowering of breathing frequency) for an 8-week study period. MAIN OUTCOMES AND MEASURES: Systolic and diastolic blood pressure measured in the physician's office. RESULTS: Forty-eight patients were randomized; 21 patients (88%) in the intervention group and 24 patients (100%) in the control group completed the study. There were no significant changes in systolic and diastolic blood pressure, with a difference in systolic blood pressure of 2.35 mmHg (95% CI -6.50 to 11.20) in favor of the control group and a difference in diastolic blood pressure of 2.25 mmHg (95% CI -2.16 to 6.67) in favor of the intervention group. Three patients in the intervention group experienced adverse events. CONCLUSIONS AND RELEVANCE: This high methodologic quality study shows no significant effect of device-guided lowering of breathing frequency on office-measured blood pressure in patients with type 2 diabetes. On the basis of this study, together with results from all but one previous trial, device-guided lowering of breathing frequency does not appear to be a viable nonpharmacologic option for hypertension treatment.
|